# Q Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/q-bio

- Industry: Biotechnology
- Headquarters: San Carlos, US
- Website: www.q.bio
- Total disclosed funding: $67M
- Latest round: Series C (Mar 26, 2024)
- Investors on record: 9

## About

Q Bio, Inc. is a US-based healthcare technology firm dedicated to transforming physical examinations through its innovative Gemini Exam, which integrates various health assessment technologies for improved patient care.Founded in 2015 and headquartered in San Carlos, US, Q Bio, Inc. specializes in advanced health assessments. The company was co-founded by Garry Choy and Jeffrey Kaditz, with Kaditz also serving as the current CEO. Q Bio has secured a total of USD 27.10 mn in funding from multiple rounds including its most recent Series C round on March 26, 2024, featuring investors such as Andreessen Horowitz, Founders Fund, Kaiser Permanente, Khosla Ventures, and TELUS Ventures. This brings their total capital raised to USD 27.10 mn with a current company valuation of USD 165.26 mn.Q Bio specializes in transforming the physical examination process through its flagship product, the Gemini Exam. This innovative service integrates lab tests, genetic profiling, vital sign monitoring, and advanced MRI technologies to provide comprehensive health assessments. The Gemini Exam automates data collection, triage, and routing to enhance preventive healthcare, enabling clinics to conduct up to 20,000 examinations annually. By utilizing individual medical histories alongside wearable and lifestyle data, Q Bio develops a personalized Digital Twin for each patient, tracking and mapping health over time. Its target clientele comprises healthcare providers, clinics, and end-users seeking proactive health management solutions, primarily in the United States and Europe.Revenue for Q Bio is generated through its innovative service offerings, particularly the Gemini Exam, which is marketed to healthcare institutions on a subscription basis. This model facilitates ongoing access to the company's technology and data analytics capabilities, allowing clinics to implement systematic patient health monitoring. Transactions occur through direct partnerships with healthcare providers, enabling them to offer Q Bio's services to their patients. Pricing structures reflect the comprehensive nature of the exams and the ongoing support provided in utilizing the Digital Twin technology, positioning Q Bio well within the expanding healthcare technology market.On March 26, 2024, Q Bio, Inc. raised USD 27.10 mn in Series C funding, which will be utilized for the production of its products. The company aims to enhance its product offerings and expand its markets, focusing on increasing accessibility of its advanced health technologies. Specific geographical regions targeted for expansion include both the US and Europe, with plans to strengthen its market presence in the upcoming years.

## Funding rounds

- Series C, Mar 26, 2024, $27M — TELUS Ventures, Founders Fund, Khosla Ventures, Andreessen Horowitz, Kaiser Foundation Hospitals
- Series B, Feb 4, 2020, $40M — Andreessen Horowitz
- Series A, Jan 1, 2018 — Khosla Ventures, Andreessen Horowitz, Sea Lane Ventures, Thirty5 Ventures
- Seed, Jan 1, 2016 — Founders Fund, Andreessen Horowitz, Beast Ventures, SciFi VC

## Investors

- Founders Fund (https://capitalatlas.ai/funds/founders-fund) — Seed, Series C
- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Seed, Series A, Series B, Series C
- Beast Ventures (https://capitalatlas.ai/funds/beast-ventures) — Seed
- SciFi VC (https://capitalatlas.ai/funds/scifi-vc) — Seed
- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series A, Series C
- Sea Lane Ventures — Series A
- Thirty5 Ventures (https://capitalatlas.ai/funds/thirty5-ventures) — Series A
- TELUS Ventures (https://capitalatlas.ai/funds/telus-ventures) — Series C
- Kaiser Foundation Hospitals — Series C